By any measurement the U.S. biotechnology industry is the envy of the world. Perspectives on the reasons for the nation's dominance in this sector are provided by the latest Scientific American Worldview Scorecard, which for the past five years has been ranking countries on their global competitiveness in biotechnology. The 2013 edition reflects increased global competition and a growing list of countries being added to the rankings. Read More
As regulators, payers and drug developers become more comfortable with their use, interest in companion diagnostics to help direct targeted medicines to the right patient populations has surged in the past couple of years. Drug companies are certainly recognizing that companion diagnostics, when co-developed with potential therapeutics, can assist in regulatory approvals. Read More
Array BioPharma Inc., a biotech known for its drug discovery engine, is expanding its capabilities, starting its first Phase III clinical trial for MEK 162. (See BioWorld Today, May 8, 2013.) Read More
